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Abstract: Flow cytometry remains a commonly used methodology due to its ability to characterise
multiple parameters on single particles in a high-throughput manner. In order to address limita-
tions with lacking sensitivity of conventional flow cytometry to characterise extracellular vesicles
(EVs), novel, highly sensitive platforms, such as high-resolution and imaging flow cytometers, have
been developed. We provided comparative benchmarks of a conventional FACS Aria III, a high-
resolution Apogee A60 Micro-PLUS and the ImageStream X Mk II imaging flow cytometry platform.
Nanospheres were used to systematically characterise the abilities of each platform to detect and
quantify populations with different sizes, refractive indices and fluorescence properties, and the
repeatability in concentration determinations was reported for each population. We evaluated the
ability of the three platforms to detect different EV phenotypes in blood plasma and the intra-day,
inter-day and global variabilities in determining EV concentrations. By applying this or similar
methodology to characterise methods, researchers would be able to make informed decisions on
choice of platforms and thereby be able to match suitable flow cytometry platforms with projects
based on the needs of each individual project. This would greatly contribute to improving the
robustness and reproducibility of EV studies.
Keywords: extracellular vesicles; exosomes; microvesicles; flow cytometry; imaging flow cytom-
etry; high-resolution flow cytometry; submicron particle analysis; standardisation; repeatability;
reproducibility
1. Introduction
Over the years, several methodological platforms have been developed and used to
characterise extracellular vesicles (EVs) in biological samples. Two common methodologies
used to characterise the size and concentration of EVs in samples are nanoparticle tracking
analysis (NTA) [1] and tuneable resistance pulse sensing (TRPS) [2]. While capable of
detecting particles in size range of EVs, NTA and TRPS lack the ability to discriminate
between EVs and other particles with similar physical properties, such as lipoproteins,
co-isolated protein aggregates and label aggregates or micelles [3–7]. Therefore, it has been
recommended that they be supplemented with other methods to confirm the presence of
proteins associated with the EV proteome in the sample, such as Western blot, ELISA or
bead-based flow cytometric characterisation [8–10]. However, these methods only provide
information on the content of specific EV markers in the bulk of the sample or EV isolates
and are unable to distinguish between variations in the number of EVs or differences in the
expression of the specific marker, and, at best, they only provide tentative evidence that the
marker of interest is present on EVs. Therefore, it has become common practice to further
supplement these methods with transmission electron microscopy (TEM) to confirm the
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presence of these markers on the surface of EVs, determine EV sizes and physical properties,
to some extent, and the presence of other contaminants in the sample [11–13]. Thus, the
whole process becomes quite labour intensive, expensive and time consuming while
remaining incapable of multi-parametric characterisation of single particles.
As such, flow cytometry has remained a popular method for the characterisation of
EVs since it provides the ability to characterise multiple parameters on single particles in a
high-throughput manner while providing some information regarding their size based on
the relative amount of scattered light. However, it has been well documented that most
conventional flow cytometers have a lower detection limit between 300 nm and 500 nm and
a best-case minimal detection limit of about 150 nm by using optimised triggering strategies,
thereby excluding the abundantly present smaller EVs from the analysis [14–16]. Another
significant limitation with conventional flow cytometers is the detection of multiple EVs as
a single event—so-called coincident or “swarm” detection—which is due to the fluidics
being optimised for characterisation of particles in the size range of cells (2–30 µm) [17–19].
Therefore, due to only being able to detect a small proportion of EVs and exosomes
regardless of characterisation strategy and the possibility of detecting multiple EVs as a
single event, the applicability of conventional flow cytometers in the field of EV research
has been widely disputed.
In order to address the limitations of conventional flow cytometers in EV characteri-
sation, several attempts have been made to increase their sensitivity towards these small
particles, thereby giving rise to high-resolution flow cytometers (hFCM). Common modifi-
cations include changing photodiodes on light scatter channels to photomultiplier tubes
(PMTs), the addition of a reduced wide-angle forward scatter/medium-angle light scatter
(MALS) collection, installation of lasers with higher power and decreases in sample and
sheath flow rates [20–23]. With these modifications, high-resolution flow cytometers have
been reported to have a lower detection limit below that of conventional flow cytometers
based on the detection of synthetic nanospheres, and their use is becoming increasingly
prevalent in the field of EV research [14,20,22–24].
Advanced imaging flow cytometry has previously been shown to have a significant
advantage towards detection and characterisation of particles in the submicron range by
being able to detect synthetic nanospheres with sizes down to 20 nm [25]. Much of this
increased sensitivity is owed to the usage of charge-coupled device (CCD) cameras, which
have a much larger dynamic range and lower noise than PMTs. Another significant factor
that improves the ability of imaging flow cytometers to detect dim signals is time delay
integration (TDI) of pixel intensities of each particle as it flows past the CCD cameras.
Along with slow sheath and sample flow rates, this allows for longer signal integration
times for each particle, thus leading to increased sensitivity. Additionally, unlike traditional
flow cytometry, images of all particles acquired are saved, thereby allowing for far more
powerful data analysis and event classification. As such, imaging flow cytometry has been
demonstrated to be an efficient tool for characterising EVs [26–29].
Even though these and other platforms have been available for some time, few at-
tempts have been made to benchmark different platforms in a fair comparative manner.
Thus, the aim of this study was to provide a benchmark of a conventional flow cytometer,
a high-resolution flow cytometer and an imaging flow cytometer. First, we assessed the
ability of each platform to detect, resolve and quantify particles within the EV size range.
Next, we evaluated their ability to detect different EV phenotypes directly in a complex
biological fluid using blood plasma as a surrogate. Finally, intra-day, inter-day and global
variability in detecting different EV phenotypes in blood plasma were determined for
each platform.
2. Materials and Methods
2.1. Collection of Platelet-Poor Blood Plasma
Blood for this study was collected from anonymous healthy Danish blood donors and
kindly donated by the Danish Blood Bank (Department of Clinical Immunology, Aalborg
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University Hospital, Aalborg, Denmark) in accordance with local ethical regulations re-
garding health scientific research on anonymous human biological material (Komitéloven
§14, stk. 3) and the Helsinki Declaration. Waste blood used to prime the tube prior to blood
donation was collected into BD Vacutainer™ 9NC tubes containing a final concentration of
0.0105M NA3 Citrate (BD Biosciences, San Jose, CA, USA, Cat. no. 366075), and platelet-
poor plasma (PPP) was acquired by a two-step centrifugation procedure initiated within
an hour after collection, as previously described [30]. First, whole blood was centrifuged at
2500× g for 15 min at room temperature, after which platelet-rich plasma was collected
>1 cm above the buffy coat and transferred into a new tube. Second, platelet-rich plasma
was subjected to additional centrifugation at 2500× g for 15 min at room temperature,
and PPP was collected > 1 cm above the pellet and transferred into a container, where all
samples were pooled. Finally, the PPP pool was thoroughly mixed and divided into 0.5 mL
aliquots in 1.5 mL tubes and stored at −80 ◦C until use.
2.2. Staining of Platelet-Poor Plasma
Prior to labelling, PPP was thawed at room temperature. Thawed PPP was centrifuged
at 1850× g for 5 min to remove potential clots that formed during freezing/thawing, and
the supernatant was transferred to a separate tube, from which it was aliquoted. Antibodies
were centrifuged at 17,000× g for 10 min prior to staining, and a master mix was prepared
of both specific and matched isotype control antibodies, as described in Table 1. In brief,
fluorescein isothiocyanate (FITC)-conjugated Lactadherin, a protein molecule that binds to
the lipid phosphatidylserine in a stereospecific and calcium-independent manner [31], was
used in both the specific and isotype control master mixes to detect phosphatidylserine-
exposing EVs. In the specific antibody master mix, allophycocyanin (APC)-conjugated anti-
CD41 antibody against the platelet surface marker CD41 abundantly expressed on platelet
EVs [32] and phycoerythrin (PE)-conjugated anti-CD36 antibody against the class B lipid
scavenger receptor CD36 present on most cells [33] were used to identify EV populations
that could be discriminated easily and less easily from the background, respectively. In the
isotype control master mix, specific isotype control antibodies were used for anti-CD41 and
anti-CD36 matched on the organism, immunoglobulin class (heavy chain and light chain),
clonality and fluorophore:protein ratio. Fifty microliters of PPP was labelled directly with
25 µL master mix for 30 min on ice in the dark. Unlabelled controls were prepared by
adding 25 µL buffer to 50 µL PPP, and buffer controls were prepared by adding 25 µL master
mix to 50 µL buffer and incubating in the same manner as samples. After incubation, the
reaction was halted by diluting stained samples and controls with Dulbecco’s phosphate-
buffered saline (DPBS) to a final volume of 850 µL (final dilution: 17-fold). Preparations
were kept on ice in the dark until analysis. In addition to the above-mentioned controls,
a 1% Triton X-100 detergent lysis control was prepared by transferring 180 µL of stained
samples into a pre-chilled tube containing 20 µL 10% Triton X-100. The detergent lysis
control was vortexed for 30 s, incubated for at least 30 min on ice and again vortexed for
30 s immediately prior to analysis. Finally, single-stained compensation controls were
prepared for each analysis day and platformed for FITC, PE, and APC.
Table 1. Antibody master mix for flow cytometric characterisation of EVs in a single 50 µL PPP sample.
Specific Antibody Sample Mix Isotype Control Antibody Sample Mix
10 µL Lactadherin-FITC (83 µg/mL, DF 1×; Haematologic
Technologies Inc., Essex Junction, VT, USA; Cat. no.
HALOBLAC-FITC)
10 µL Lactadherin-FITC (83 µg/mL, DF 1×; Haematologic
Technologies Inc., Essex Junction, VT, USA; Cat. no.
HALOBLAC-FITC)
10 µL anti-CD41-APC (25 µg/mL, DF 1×; Clone HIP8;
Biolegend, San Diego, CA, USA; Cat. no. 303710)
10 µL IgG1, κ-APC (200 µg/mL, DF 8×; Clone MOPC-21;
Biolegend, San Diego, CA, USA; Cat. no. 400120)
5 µL anti-CD36-PE (200 µg/mL, DF 1×; Clone 5–271; Biolegend,
San Diego, CA, USA; Cat. no. 336206)
5 µL IgG2a, κ-PE (200 µg/mL, DF 1×; Clone MOPC-173;
Biolegend, San Diego, CA, USA; Cat. no. 400212)
Abbreviations: EVs: extracellular vesicles; PPP: platelet-poor plasma; FITC: fluorescein isothiocyanate; APC: allophycocyanin; PE:
phycoerythrin; DF: dilution factor prior to the preparation of master mix.
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2.3. BD FACSAria™ III
Conventional flow cytometry was performed on a BD FACSAria™ III High-Speed
Cell Sorter (BD Biosciences, San Jose, CA, USA) equipped with 375 nm (7 mW), 488 nm
(20 mW) and 633 nm (18 mW) lasers. The 488 nm and 633 nm lasers were run at maximum
power, while the 405 nm laser was turned off and not utilised in this study. Forward scatter
(FSC) and side scatter (SSC) were collected from the 488 nm laser into a photodiode and a
PMT, respectively. FITC was collected from the 488 nm laser through a 530/30 bandpass
filter. PE was collected from the 488 nm laser through a 585/42 bandpass filter. APC was
collected from the 633 nm laser through a 660/20 bandpass filter. Data were acquired for
180 s at 70 psi and a sample flow rate set to 2 to allow for a narrow sample core while
maintaining an adequate event rate. Nanosphere samples were either acquired with a
triggering threshold set to 200 on side scatter or FITC. All other samples were acquired with
a triggering threshold set to 200 on FITC. Triggering thresholds were set above electronic
noise, while PMT voltages on forward and side scatter were adjusted to give the optimal
separation between background and the smallest discriminable nanosphere population in
the mixture described below. Similarly, the triggering threshold was set to 200 on FITC,
and the PMT voltage was adjusted to give the optimal separation between background
and fluorescent nanospheres in the same mixture. Instrument settings were adjusted, and
the data were recorded in BD FACSDiva Software v. 8.0.2 (BD Biosciences). All data from
the FACS Aria III was acquired in the FCS v. 3.1 format and processed in FlowJo v. 10.5.3
(FLowJo LLC, BD Biosciences, San Jose, CA, USA).
2.4. Apogee A60 Micro-PLUS
High-resolution flow cytometry was performed on an A60 Micro-PLUS flow cytometer
(Apogee Flow Systems, Hemel Hempstead, UK) equipped with 405 nm (300 mW), 647 nm
(180 mW) and 488 nm (200 mW) diode lasers. The 405 nm laser was run at 190 mW, while
the 488 nm and 638 nm lasers were run at 100 mW. Three PMTs were factory-fitted for the
collection of small-angle light scatter (SALS), medium-angle light scatter (MALS) and large-
angle light scatter (LALS) signals collected from the 405 nm laser after being separated
from fluorescence signals on this laser by an LP415 long-pass filter. FITC signals were
collected from the 488 nm laser into a PMT fitted with a 530/40 bandpass filter, PE signals
were collected from the 488 nm laser into a PMT with a 575/30 bandpass filter, and APC
signals were collected from the 638 nm laser into a PMT with a 680/35 bandpass filter. Data
were acquired for 180 s at a sample flow rate of 0.75 µL/min and a sheath fluid pressure
of 150 mBar in order to keep the sample core as tight as possible and allow for adequate
exposure of EVs by the lasers. Nanosphere samples were acquired with a triggering
threshold set to 30 on MALS corresponding to an intensity value of 1920 on this parameter.
Plasma samples were acquired with a triggering threshold set to 30 on MALS and 20 on
FITC, which correspond to values of 1920 and 1280 on these channels, respectively. The
triggering threshold on MALS was set to allow the collection of 100 events/second in
unlabelled PBS, whereas the triggering threshold on FITC was set to allow the acquisition
of 100 events/second in unlabelled PPP. Instrument settings were adjusted, and the data
were recorded in the Histogram v. 1.21 software utility (Apogee Flow Systems, Hemel
Hempstead, Hertfordshire, UK). All data from the A60 Micro-PLUS were acquired in the
FCS v. 3.0 format and analysed in FlowJo.
2.5. Amnis® ImageStream® X Mk II
Imaging flow cytometry was performed on an ImageStream X Mk II imaging flow
cytometer (Luminex Corporation, Seattle, WA, USA). The ImageStream X Mk II was
equipped with 488 nm (200 mW), 642 nm (150 mW), 405 nm (120 mW), 785 nm (70 mW),
561 nm (200 mW) and 592 nm (300 mW) lasers. All lasers were run at their maximum power
with the exception of the 561 nm and 592 nm lasers, which were turned off completely
and not utilised in this study. All signals were collected into 12 channels distributed on
two charge-coupled devices (CCDs) with 6 channels per camera with a filter setup. The
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notch filter on the 405 nm laser containing a 435 nm longpass filter was removed from
the 405 nm laser in order to enable acquisition of side scatter from this laser in channel 7
(Ch07) in addition to side scatter from the 785 nm laser, which was collected into channel 6
(Ch06). FITC signals were collected from the 488 nm laser into channel 2 (Ch02) on camera
1 through a 528/65 bandpass filter. PE was collected from the 488 nm laser into channel 3
(Ch03) on camera 1 through a 577/35 bandpass filter. APC signals were collected from the
642 nm laser into channel 11 (Ch11) on camera 2 through a 702/85 bandpass filter. One
channel on each CCD (channel 1 and channel 9; Ch01 and Ch09, respectively) was reserved
for the bright field (BF) and used for cross camera alignment of the two CCDs. Data
acquisition was disabled for all other channels than the above-mentioned. Speed beads
(1.0 ± 0.2 µm COOH-functionalised polystyrene beads, Refractive Index (RI) = 1.63) were
run constantly during sample acquisition and used for sample core alignment, focussing
and camera synchronisation. Data were acquired for 180 s at 60× magnification with a
numerical aperture of 0.9 and image resolution of 0.3 × 0.3 µm/pixel with extended depth
of field (EDF) turned off. The diameter of the sample core was adjusted to and kept at
6 µm to keep most particles in focus while maintaining reasonable sample core stability.
Data acquisition was initialized approximately three minutes after loading each sample,
as this was the time required for event rates to stabilise due to dilution of the sample
with sheath fluid. Instrument settings were adjusted, and the data were recorded in the
INSPIRE™ v200.1.388 software utility (Luminex Corporation, Seattle, WA, USA). Data
were saved as raw image files (RIF) after the acquisition. After compensation and data
analysis, compensated (CIF) and data analysis file (DAF) were created for each file. Data
from nanosphere mixtures were first compensated for fluorescence spill-over in IDEAS® v.
6.2, and CIF/DAF files exported as FCS files, which were then analysed in FlowJo v. 10.5.3.
All other analyses were performed in IDEAS. Initially, the standard “Mask Combined”
(MC) masking settings were used, which is based on Boolean OR logic, where any signal in
any of the acquired channels contributes to the constructed mask. However, due to most
small nanospheres and EVs not having a visible signal in the bright field channel, these
channels were found to create artefacts, which resulted in erroneous quantification in other
channels. Thus, a new mask was constructed for all other channel masks (“M + channel
number”) in which bright field masks were not equated (“M02 OR M03 OR M06 OR M07
OR M11”) and used instead.
2.6. Detection and Quantification of Silica and Polystyrene Nanospheres
In order to compare the ability of the different platforms to measure particles in
the EV size, light scatter and fluorescence range, a mixture of non-fluorescent silica and
fluorescent polystyrene nanospheres was used. The mixture consisted of 850 µL Apogee
Mix (Apogee Flow Systems; Cat. no. 1493; Lot. no. CAL0098) spiked with 200 times
pre-diluted 280 nm multi-fluorescent Ultra Rainbow Beads (Spherotech Inc., Lake Forest,
IL, USA; Cat. no. URFP-02-2), thereby yielding a mixture with the following populations:
180 nm, 240 nm, 300 nm, 590 nm, 880 nm and 1300 nm non-fluorescent silica nanospheres
(RI = 1.47) and 110 nm yellow-green fluorescent, 280 nm multi-fluorescent and 500 nm
yellow-green fluorescent polystyrene nanospheres (RI = 1.63). For platforms capable of
detecting the 180 nm non-fluorescent silica nanosphere population, in-house 100 nm yellow-
green silica nanospheres were additionally analysed in order to investigate their ability to
discriminate particles with very little light scatter from the background. Further details on
data acquisition and analysis can be found in the appropriate sections of methods for each
platform, results and figure legends.
2.7. Flow Cytometric Characterisation of EVs
The general gating strategy for defining the different EV phenotypes on all platforms
in this study is depicted in Figure 1, with platform-specific strategies depicted in supple-
mentary Figures S1–S3. First, a <1000 nm size gate was established on a sample of 1000 nm
yellow-green fluorescent silica nanospheres (RI = 1.47), encompassing all values below
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the 99th percentile of the 1000 nm bead population on forward scatter and side scatter
(FACS Aria III and A60 Micro-PLUS; Figure 1A) or 405 nm side scatter alone (ImageStream
X Mk II; Figure 1B). Next, a phosphatidylserine (PS) expression gate (Figure 1C) was
established on all events <1000 nm silica in the lactadherin-FITC channel on an unlabelled
PPP sample (A60 Micro-PLUS and ImageStream X Mk II) or set to the triggering threshold
value on the FITC channel (FACS Aria III). Phenotype gates were then defined on bi-variate
plots of PS-expressing events in a PPP sample stained with isotype control antibodies of
CD36-PE and CD41-APC channels using quadrant gates on the 99th percentiles of both
parameters to define events positive for the expression of these markers (Figure 1D). Finally,
Boolean logic gates were used to define the total number of CD36+ and CD41+ events
(FACS Aria III and A60 Micro-PLUS). On the ImageStream X Mk II, however, PS+|CD41+,
PS+|CD36+ and PS+|CD41+|CD36+ different phenotypes were defined separately with
square gates instead on a bivariate plot of CD41 and CD36 expression (Figure 1G and
Figure S3). Thus, four phenotypes were defined as being of interest in this benchmarking
study: the EV-defining PS+ phenotype; an easily discriminable PS+|CD41+ phenotype; a
less discriminable PS+|CD36+ phenotype; a triple-stained PS+|CD41+|CD36+ phenotype.
These phenotypes are depicted in Figure 1E–G.
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Figure 1. EV-defining gating strategy and depiction of representative data for each of the three flow cytometry platforms.
(A–D) Schematic depiction of the gating strategy used for defining EV phenotypes in PPP samples. (A) First, a size gate was
established on the 99th percentile of green fluorescent 1000 nm silica nanospheres (RI 1.42) on FSC/SALS vs. SSC/LALS
on FACS Aria III and Apogee A60 Micro-PLUS or (B) on 405 nm SSC alone on ImageStream X Mk II. (C) Next, on events
within the EV size gate in an unlabelled PPP sample, a gate was established on the 99th percentile in the FITC channel to
define lactadherin-binding phosphatidylserine (PS)+ events (Apogee A60 Micro-PLUS and ImageStream X Mk II) or set
to the triggering threshold value of 200 (FACS Aria III). (D) On PS+ events in a PPP sample stained with isotype control
antibodies, quadrant gates were established on the 99th percentiles of events in the APC vs PE channels to define different
combinations of CD41+/− and CD36+/− events, respectively. (D) Finally, the sums of CD41+ and CD36+ events were
defined by establishing logical OR gates on “CD41+|CD36+ OR CD41+|CD36−“ and “CD41−|CD36+ OR CD41+|CD36+”,
respectively. (E–G) Representative histograms of PS+ events (left) or scatterplots of CD41+/−|CD36+/− events (right) for
(E) FACS Aria III, (F) Apogee A60 Micro-PLUS and (G) ImageStream X Mk II. EV: Extracellular vesicle; PPP: Platelet poor
plasma; PS: Phosphatidylserine; FITC: Fluorescein isothiocyanate; APC: Allophycocyanin; PE: Phycoerythrin; SSC: Side
scatter; LALS: Large angle light scatter.
In order to assess whether true EV phenotypes were being measured, different controls
were employed to account for common artefacts and pitfalls. Unlabelled samples were used
to establish the EV-defining gate of this study, thereby excluding a large proportion of non-
EV particles from the analysis. Similarly, gating on well-defined isotype controls limited
the inclusion of events resulting from non-specific binding of antibodies and fluorescence
background caused by the unbound stain. Buffer controls stained with either specific or
isotype control master mixes were analysed in order to account for the presence of label
aggregates in samples, which could confound EV concentrations and confer variability
across analysis days. Detergent lysis controls were analysed in order to assess whether
the measured phenotypes contained membrane-like structures, which are disrupted when
detergent is added. Population distributions and concentrations of all phenotypes were
comparatively analysed between samples labelled with specific antibodies and controls. For
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each platform, a serial dilution control of the sample was prepared to ensure detection of
single events, where event rate linearity and median fluorescence signal intensity stability
were evaluated within this range (dilution factors: 5, 9, 17, 33 and 65-fold). Controls are
depicted in supplementary results (Figures S4–S7).
Gates were constructed for each analysis day and transferred to all samples and
controls from the same analysis day. Concentrations were calculated as the number of
events divided by the sample volume and multiplied by the dilution factor. For the FACS
Aria, however, BD TruCount™ counting beads (BD Biosciences, Cat. no. 340334) were
utilised to account for the instability of the sample flow rate. Here, the concentrations
were calculated based on the number of measured counting beads, as specified by the
manufacturer in the technical datasheet. All statistics were batch exported as either .xls files
(FACS Aria III, A60 Micro-PLUS) or .CSV files (ImageStream X Mk II) for further analysis.
2.8. Data Analysis
Data processing and statistical data analysis were performed in R v. 3.5.1 (R Core
Team, Vienna, Austria) in RStudio v. 1.1.456 using the xlsx [34], ggplot2 [35], reshape2 [36]
and grid [37] packages installed. The assumption of normality was tested with Shapiro–
Wilk’s W-test for normality and confirmed with QQ-plots and histograms of distributions.
Homoscedasticity was assessed with Levene’s test for equal distributions and confirmed
visually with different plots. Due to either non-normal distributions or heteroscedasticity
between groups, the unpaired Wilcoxon Rank Sums test was used to compare parameters
between groups. p-values were adjusted with Holm’s sequentially rejective multiple test
procedure [38]. All p-values were reported as two-sided, and statistical significance was
defined as p < 0.05.
3. Results
3.1. Detection and Quantification of Synthetic Nanospheres with Different Sizes and
Refractive Indices
In order to characterise the bulk of EVs effectively, instruments must be able to reliably
detect, quantify and gather light scatter and fluorescence signals from single EVs. Thus,
we decided to compare the abilities of the four platforms to detect and quantify particles in
size, scatter and fluorescence range of EVs. To this end, we analysed a single replicate of
a mixture of synthetic nanospheres consisting of nine different nanosphere populations
with defined sizes, refractive indices and fluorescence properties (non-fluorescent silica
nanospheres: 180 nm, 240 nm, 300 nm, 590 nm, 880 nm, 1300 nm; fluorescent polystyrene
nanospheres: 110 nm yellow-green fluorescent, 280 nm multi-fluorescent, 500 nm yellow-
green fluorescent). Additionally, a monodisperse solution of 100 nm dimly yellow-green
fluorescent silica nanospheres was analysed on platforms capable of discriminating 180 nm
silica beads from the background on each analysis day to assess their sensitivity in detecting
such small particles.
Previous studies have mainly focussed on the ability of flow cytometers to detect and
discriminate particles of different sizes from each other on single light scatter parameters
when determining instrument sensitivity [24,25,29,39]. We, however, decided against
this approach, as discrimination of particles with different sizes in this manner is highly
dependent on collection angles, light sources and optics utilised in the system [40], and
better results can often be obtained by using more than one parameter when gating
populations in samples. Instead, we determined the limits of detection (LoD) and limits
of quantification (LoQ) for each platform and compared their abilities to quantify each
individual nanosphere population.
3.1.1. Limits of Detection and Quantification
In this study, LoD was defined as the smallest nanosphere population, which could
be confidently identified and discriminated from the background and other nanosphere
populations. LoQ was defined as the smallest bead population, which could be quantified
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with sufficient reproducibility. In terms of reliability, we decided on an arbitrary accuracy
goal of coefficient of variability (CV) less than 20%. In a sense, it can be assumed that
LoD ≤ LoQ. In order to maximise instrument performance, we decided to use optimal
instrument settings and gating strategies for each platform.
By using a triggering threshold set to 200 on SSC, FACS Aria III was unable to de-
tect and resolve silica nanosphere populations below 300 nm or the 110 nm fluorescent
polystyrene nanospheres (Figure 2A). When using a triggering threshold set to 200 on the
green channel on the 488 nm laser (FITC), as previously described by Arraud et al. [15,16],
FACS Aria III could detect 110 nm fluorescent polystyrene nanospheres with light scatter
below the 300 nm silica nanospheres. However, this was at the cost of the non-fluorescent
silica nanosphere populations and the dimly fluorescent 280 nm polystyrene nanospheres,
where the latter could not be resolved from non-fluorescent populations regardless of
triggering threshold (Figure 2B). Although able to detect different nanospheres, FACS
Aria III could not quantify any of these with a sufficient reproducibility (Figure 3A,
CV = 22.4–36.1%).
Apogee A60 Micro-PLUS was able to detect all nanosphere populations in the nanosphere
mixture with a triggering threshold set on MALS to filter out noise, and all nanosphere
populations could be resolved from the background on LALS. In addition, all fluorescent
polystyrene nanosphere populations could be resolved from the background based on
their fluorescence; however, the 280 nm nanospheres were only barely resolvable from
the background based on their fluorescence (Figure 2C). This setting also allowed for the
detection and identification of 100 nm dimly fluorescent silica nanospheres on a biaxial
plot of MALS and FITC, although these nanospheres could not be resolved completely
from the background based on light scatter, and they significantly overlapped background
with regards to fluorescence (Figure 2G). Moreover, all silica and polystyrene nanosphere
populations could be quantified with sufficient reproducibility (Figure 3B, CV = 3.9–9.9%).
Although ImageStream X Mk II could easily resolve all of the fluorescent polystyrene
nanospheres clearly on fluorescence and subsequently on 405 nm SSC and 785 nm SSC, this
was not the case for the non-fluorescent silica nanospheres, all of which drowned in the ex-
cessive background on the two SSC parameters (Figure 2D). In order to reduce the amount
of background, we attempted several approaches, such as discriminating background from
true nanosphere events in different combinations of bivariate plots of a range of calculated
features, including but not limited to the aspect ratio, mask area, gradient root mean
square (RMS), unmasked channel intensity, Haralick texture features and different masking
strategies (data not shown). However, we found that the best and most elegant approach
to circumvent this issue was to identify silica nanospheres on a bivariate scatter plot of
non-fluorescent events on 405 nm SSC vs 785 nm SSC (Figure 2E). By using this approach, it
was possible to identify all of the silica nanospheres present in the mixture. However, they
were located within a significant background of unknown origin, which was present only
to a lesser degree in pure buffer samples. In addition, 100 nm silica nanospheres could be
discriminated from the background based on their fluorescence (Figure 2H), which was in
line with what was observed for the fluorescent polystyrene nanospheres. ImageStream X
Mk II could not quantify the 100 nm and 180 nm silica beads with an adequate reproducibil-
ity (CV = 48.8% and 29.5%, respectively; Figure 3C). Although ImageStream X Mk II could
quantify 240–590 nm silica nanospheres reliably (CV = 8.9–11.7%), greater variability was
observed for 880 nm and 1300 nm silica nanospheres (CV = 24.3 and 28.8%, respectively).
Interestingly, 110 nm and 500 nm polystyrene nanospheres could be quantified reliably
(CV = 4.5 and 8.4%); however, greater variability was observed for the 280 nm population
(CV = 25.4%).
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Figure 2. Detection and quantification of nanospheres with different refractive indices. (A–G) Gating strategy to define
each nanosphere population in the bead mixture on (A) FACS Aria III for triggering in the FITC and (B) SSC, (C) Apogee
A60 Micro-PLUS and (D,E) ImageStream X Mk II. (F,G) Gating strategy to define dimly FITC fluorescent 100 nm silica
nanospheres on (F) Apogee A60 Micro-PLUS and (G) ImageStream X Mk II. (H) Concentrations of silica (top) and fluorescent
polystyrene (bottom) nanosphere populations measured by each of the four platforms with an indication to their relative
light scatter. Results are depicted as mean (bar) ± 1SD (error bars) for n = 5 observations of each nanosphere population
acquired over the course of five analysis days. Numbers in A-E represent different nanosphere populations as follows:
1: Ps110 nm; 2: Ps280 nm; 3: Ps580 nm; 4: Si180 nm; 5: Si240 nm; 6: Si300 nm; 7: Si590 nm; 8: Si880 nm; 9: Si1300 nm;
10: Si100 nm; B: Background. *: p < 0.05; **: p < 0.01. N.D.: Not detected; RI: Refractive Index; MALS: Medium angle
light scatter.









































































































































Figure 3. Variability in concentration determinations of synthetic nanospheres on (A) FACS Aria
III, (B) Apogee A60 Micro-PLUS and (C) ImageStream X Mk II. The horizontal red, dashed line
represents the arbitrary limit of quantification (LoQ) set in this study to a coefficient of variability
(CV) of less than 20% for concentrations of synthetic nanospheres. CV: Coefficient of variability =
standard deviation (SD)/mean for n = 5 per nanosphere population per platform; N.D.: Not detected.
Thus, using the optimal triggering threshold and gating strategies, Apogee A60
Micro-PLUS and ImageStream X Mk II had the lowest LoDs by being able to detect the
smallest silica nanospheres, followed by FACS Aria III. In being fluorescent and thereby
discriminable from the background, 110 nm fluorescent polystyrene nanospheres could be
detected by both FACS Aria III, thereby resulting in a slightly lower functional LoD for this
platform than determined with silica nanospheres. Apogee A60 Micro-PLUS had the lowest
LoQ by being able to quantify all bead populations with adequate reproducibility. This
was followed by ImageStream X Mk II, as determined with silica nanospheres. In line with
observations for LoD, ImageStream X Mk II had a lower functional LoQ when assessed by
polystyrene nanospheres due to their fluorescent properties, making them discriminable
from the background. FACS Aria III could not quantify any of the nanospheres used in the
mixture with adequate reproducibility.
3.1.2. Quantifying Nanospheres in Practice
Although LoD and LoQ are useful to define the smallest particles that can be detected
and discriminated from the background and quantified with satisfactory accuracy, respec-
tively, they do not convey the ability of a cytometer to detect particles of different sizes.
Therefore, we compared the concentrations of the different nanospheres between platforms
in order to address this problem (Figure 2H).
When assessing the ability to detect small silica nanospheres (100–300 nm), Apogee
A60 Micro-PLUS clearly outperformed both ImageStream X Mk II. Apogee A60 Micro-PLUS
detected 24.6-fold more of the 100 nm population (p < 0.01), 1.4-fold more of the 180 nm
population (p = 0.056, N.S.), 1.7-fold more of the 240 nm population (p < 0.05) and 1.7-fold
more of the 300 nm population (p < 0.05) compared to ImageStream X Mk II. Although
it could be argued that background could significantly contribute to the concentration of
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100 nm silica nanospheres measured on Apogee A60 Micro-PLUS due to them not being
able to be fully resolved, this was verified not to be the case by assessing the concentration
of pure buffer and the nanosphere mixture lacking 100 nm silica nanospheres in the 100 nm
population gate (Figure S7). Interestingly, FACS Aria III detected more of the 300 nm
populations compared to all of the other platforms (Apogee A60 Micro-PLUS: 1.6-fold,
p < 0.05; ImageStream X Mk II: 2.7-fold, p < 0.05). Although the underlying reason for this
difference is somewhat unclear, a possible explanation could be that a proportion of the
240 nm nanospheres in the mixture was detected in the same region as 300 nm nanospheres
on FACS Aria III due to a lack of sensitivity and ability to resolve these particles.
In contrast to the small silica nanospheres, differences between FACS Aria III, Apogee
A60 Micro-PLUS and ImageStream X Mk II were less pronounced for the larger silica
nanospheres (590 nm, 880 nm and 1300 nm) with the only statistically significant difference
being in the concentration of the 590 nm population between Apogee A60 Micro-PLUS and
ImageStream X Mk II (1.2-fold, p < 0.05).
Similar tendencies were observed for fluorescent polystyrene nanospheres. As with
small silica nanospheres, Apogee A60 Micro-PLUS could detect more of the 110 nm popu-
lation than FACS Aria III (1.5-fold, p < 0.05) and ImageStream X Mk II (1.8-fold, p < 0.05).
All platforms detected similar concentrations of the 280 nm and 500 nm population.
In line with observations for LoD and LoQ, Apogee A60 Micro-PLUS tended to be
more sensitive in detecting small silica nanospheres, scattering very small amounts of
light than all other platforms, followed by ImageStream X Mk II and, lastly, FACS Aria
III. For larger silica nanospheres, all platforms performed similarly. Finally, results for
fluorescent polystyrene nanospheres reflected those for silica nanospheres, where Apogee
A60 Micro-PLUS performed better than other platforms in detecting small nanospheres.
3.2. Detection of Different EV Phenotypes in Blood Plasma
One of the main aims of this study was to assess the ability of the different FCM
platforms to detect and characterise different EV phenotypes directly in complex bio-
fluids. To this end, 40 aliquots of the same PPP pool were stained directly with antibodies
against EV markers expressed to varying degrees, defining four different phenotypes, and
measured on each platform over the course of five analysis days (Figure 1E–H). The global
mean concentrations of all samples for each phenotype were then statistically compared
between platforms (Figure 4A–D).
Regarding the detection of the single-labelled, EV-defining PS+ EV phenotype (Figure 4A),
ImageStream X Mk II detected a 21-fold greater concentration compared to FACS Aria
III (p < 0.001) and 8.3-fold greater concentrations compared to Apogee A60 Micro-PLUS
(p < 0.001). The Apogee A60 Micro-PLUS detected 2.6 (p = 0.008) more EVs than FACS
Aria III.
Concerning the easily discriminable double-labelled PS+|CD41+ phenotype (Figure 4B),
differences between ImageStream X Mk II and other platforms were less pronounced albeit
somewhat comparable to the results on PS+ EVs, detecting 6.2-fold greater concentrations
compared to FACS Aria III (p < 0.001) and 3.2-fold more than Apogee A60 Micro-PLUS
(p < 0.001). Apogee A60 Micro-PLUS detected 2.0-fold more PS+|CD41+ EVs than FACS
Aria III (p < 0.001). Somewhat similar results were obtained for the less discriminable
PS+|CD36+ double-labelled phenotype (Figure 4C). ImageStream X Mk II detected 5.2-fold
greater concentrations than FACS Aria III (p < 0.001) and 1.7-fold greater than Apogee
A60 Micro-PLUS (p < 0.001). The Apogee A60 Micro-PLUS detected a 3-fold greater
concentration than FACS Aria III (p < 0.001).
Comparing the ability of the different platforms to detect the triple-labelled PS+|CD41+
|CD36+ EV phenotype (Figure 4D), ImageStream X Mk II only detected slightly more EVs
than Apogee A60 Micro-PLUS (1.1-fold, p = 0.003), whereas ImageStream X Mk II could
detect 2.9-fold more EVs than FACS Aria III (p < 0.001). Apogee A60 Micro-PLUS could
detect 2.7-fold more EVs with this phenotype than FACS Aria III (p < 0.001).
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Figure 4. Concentrations and variability in the detection of EV phenotypes on three different flow cytometry platforms.
(A–D) Concentrations of (A) PS+, (B) PS+|CD41+, (C) PS+|CD36+ and (D) PS+|CD41+|CD36+ EVs detected on the three
different platforms. Results are depicted as mean (bar) ± 1SD (error bars) of concentrations from the inter-day variability
study. (E–H) Intra-day variability in the detection of (E) PS+, (F) PS+|CD41+, (G) PS+|CD36+ and (H) PS+|CD41+|CD36+
EVs (n = 20 per platform). (I–L) Inter-day variability in the detection of (I) PS+, (J) PS+|CD41+, (K) PS+|CD36+ and (L)
PS+|CD41+|CD36+ EVs (n = 5 × 5 per platform). (M–P) Global variability in the detection of (M) PS+, (N) PS+|CD41+,
(O) PS+|CD36+ and (P) PS+|CD41+|CD36+ EVs (n = 40 per platform). Coefficients of variability (CV) were calculated as
SD/mean expressed in percent.
Thus, taken together, ImageStream X Mk II could detect higher concentrations of EV
phenotypes than all other platforms with the exception of triple-labelled EVs, for which
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Apogee A60 Micro-PLUS could detect similar concentrations. Finally, the Apogee A60
Micro-PLUS could detect higher concentrations of all EV phenotypes compared to FACS
Aria III.
3.3. Variability in Determining EV Concentrations and Fluorescence Signals
Another main point of focus for this study was determining the variability in quanti-
fying different EV phenotypes in bio-fluids on the four platforms. We assessed intra-day,
inter-day and global variability, as all three parameters describe different aspects of stability
in measurements (i.e., measurement error during a single analysis day vs from one day to
another vs throughout a study).
Intra-day variability was investigated by labelling 20 individual aliquots of the same
PPP pool and analysing the samples on a single analysis day, which would represent
a medium to long analysis day (Figure 4E–H). ImageStream X Mk II presented with
noticeably higher intra-day variabilities for all four EV phenotypes (CV = 13.9–19.2%)
compared to all other platforms. Comparable variabilities were observed for FACS Aria III
(CV = 6.2–9.2%) and Apogee A60 Micro-PLUS (CV = 5.7–7.5%).
Inter-day variability was evaluated by labelling and analysing five individual aliquots
per day for five days on each platform and calculating the variability in daily means of
samples (Figure 4I–L). Although ImageStream X Mk II had high intra-day variabilities for
all phenotypes, it presented with the lowest overall inter-day variabilities (CV = 4.4–13.1%).
Apogee A60 Micro-PLUS demonstrated similar or only slightly increased inter-day vari-
abilities for all phenotypes compared to ImageStream X Mk II (CV = 6.3–12.7%). However,
FACS Aria III (CV = 10.9–15.0%) presented with markedly increased overall inter-day
variabilities compared to the other platforms.
In addition to intra- and inter-day variability, global variability was evaluated to
simulate the systemic measurement error incurred over multiple analysis days, as would
be the case for samples from most study cohorts. Global variability was assessed by
calculating the coefficient of variability for all 40 aliquots individually labelled throughout
the duration of this study (Figure 4M–P). Unsurprisingly, global variabilities tended to
be higher for all platforms compared to intra- and inter-day variabilities. However, the
magnitude varied between platforms. ImageStream X Mk II had the highest overall global
variability of all platforms in measuring all phenotypes (CV = 13.0–20.7%), followed by
FACS Aria III (CV = 13.5–16.9%). Finally, Apogee A60 Micro-PLUS had the lowest global
variabilities in determining all of the four phenotypes (CV = 9.3–12.5%).
In summary, the Apogee A60 Micro-PLUS demonstrated the overall lowest variabil-
ities in EV concentration determinations, and global and inter-day variabilities did not
differ much from intra-day variabilities. The FACS Aria III performed similarly and ex-
hibited somewhat increased variabilities in EV concentration determinations compared
to the Apogee A60 Micro-PLUS. Finally, although the average concentrations of EV phe-
notypes did not differ between analysis days on the ImageStream X Mk II, it presented
with the highest intra-day and global variabilities in EV concentrations across EV samples
and phenotypes.
4. Discussion
Since the early days of the field of research into EVs, flow cytometry has been a popular
method for their characterisation, as it allows for simultaneous detection of multiple
parameters on single EVs. While conventional flow cytometry is still commonly used
despite the bulk of EVs being below its lower detection limit, the increasing availability
and affordability of high-resolution and imaging platforms more sensitive to the detection
and characterisation of small particles have seen the use of these becoming more prevalent.
Although all of these platforms have been available to researchers for some time, few direct
benchmarks have been published, and the extent of published benchmarks is limited to the
smallest size of synthetic nanospheres the platform can detect and discriminate.
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In this study, the FACS Aria III has served as a comparator for the other platforms to
verify their applicability in the detection of small particles and whether these platforms pro-
vide increased capabilities for characterising single EVs in complex biological fluids. The
limitations of conventional flow cytometry represented by the FACS Aria III in this study
in detecting and characterising single EVs has been discussed quite elegantly and thor-
oughly by other authors, and little more can be contributed to this discussion [20–22,24,41].
Therefore, the following sections have focussed on discussing the other platforms utilised
in this study.
4.1. Detection of Synthetic Nanospheres
The use of synthetic nanospheres is somewhat contentious due to their physical prop-
erties often differing significantly from those of biological EVs. However, due to their
availability, uniform nature and being inexpensive, both silica and polystyrene nanospheres
are still being used for characterising the sensitivity and detection limits of FCM platforms
and are additionally used as controls and for quality assurance (QA) [25,29,30,39,42,43].
These properties allow for the inclusion of several nanosphere populations with differing
sizes, refractive indices, fluorescent properties or surface treatments to be included into
control and QA regimens. Regardless, there has been some discussion about the applicabil-
ity of synthetic nanospheres as reference controls for EVs due to their refractive indices
being far above that of EVs [41,44]. At the commonly used illumination wavelengths used
for light scatter measurements in modern flow cytometers, polystyrene nanospheres com-
monly used in characterising FCM sensitivity have a refractive index of 1.59–1.63 [45,46].
Furthermore, although silica nanospheres have a significantly lower refractive index of
1.45 [41,45–47], this is still somewhat higher than EVs, which have been estimated to have
a refractive index below 1.40 [44]. Thus, depending on the particle size, illumination
wavelength and the optical set-up of the FCM platform, polystyrene and silica nanospheres
would scatter between 40 and 300 or 5 and 50-fold more light than EVs, respectively [46–48].
While several synthetic and biological alternatives (i.e., liposomes, virus particles and hol-
low core-in-shell nanospheres) have been suggested as alternatives, these either come with
their own issues, such as non-uniformity, low reproducibility and traceability, biological
hazards or unavailability to the general research community. Thus, we opted to use a
combination of silica and polystyrene nanospheres in this study to characterise platform
sensitivity, as their uniform nature allows for easy detection and discrimination on ei-
ther single parameter histograms or multi-parameter scatterplots. In order to make the
comparison as thorough and relevant as possible, we decided to define the lower LoD of
each platform based on the smallest detectible nanosphere population. Unlike previous
studies that defined the lower LoD on the smallest nanosphere discriminable from other
nanospheres and background on a single scatter parameter [24,25,29,39], we defined the
lower LoD based on the best combination of parameters for each platform. While it could
be argued that this is not completely comparable due to potentially differing data analysis
strategies, experienced cytometrists would utilise data analysis strategies that suit their
respective platforms best and thereby gain additional sensitivity that is unattainable in a
direct comparison. In that sense, we argue that this comparison could be considered closer
to reality.
In this study, only the Apogee A60 Micro-PLUS and the ImageStream X Mk II were able
to detect all of the nanospheres used to determine LoD. Although much of this sensitivity
on both methods stem from slow sheath speeds, tight sample cores and high magnification
of the interrogation area, there are some distinct differences between these platforms.
Much of the sensitivity of the Apogee A60 Micro-PLUS is derived from a combination
of the slow sheath and sample flow rates, usage of powerful lasers for illumination of
particles in the sample core, confocal high-magnification of the interrogation zone and
several inline particle filters to remove impurities in the sheath fluid. Together, these
strategies have been shown to increase the intensity of signals captured from particles
in the sample, while decreasing the amount of background signals from impurities in
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the sheath fluid and Mie and Raleigh light scatter of laser light by particles or molecules
outside the focal plane [20–22]. According to Mie and Raleigh’s theories on light scattering
by small particles, light scatter is somewhat dependent on the wavelength of the incident
light. A significant factor to consider in this regard is the functional limit where the size
of a particle determines whether a particle transitions predominantly, conforming to one
of these theories to the other. While this limit has traditionally been set to particles much
smaller than the wavelength of the incident light, theoretical and physical experiments
have demonstrated that this limit is at particles with a diameter around one-tenth of the
wavelength of incident light [40]. Thus, the use of a 405 nm laser for light scatter instead
of the 488 nm lasers typically used in flow cytometers could contribute to the theoretical
lower limit of detection being reduced. Whether this has an effect on the detection and
discrimination of particles from the background is much more complex, however, and
other factors might contribute more to the functional sensitivity of a cytometer. First, it
is widely accepted that higher laser power also results in larger signals and separation
between background and true particles, which has been demonstrated for both fluores-
cence [49] and light scatter measurements from small particles [Botha et al., in preparation].
Thus, by utilising lasers with significantly higher power ratings than conventional systems
(180–300 mW versus 3–50 mW), the sensitivity of the Apogee A60 Micro-PLUS is further
increased. Second, a factor that is often overlooked by cytometrists in improving and dis-
cussing sensitivity to detect and discriminate particles on light scatter on a flow cytometer
is the collection angles of scattered light. Although this is a complex subject, it has been
demonstrated that collecting light in an angle between conventional FSC and SSC could
improve both the sensitivity of detecting light scatter from particles and to discriminate
them from the background [20,21]. As such, by not only acquiring signals in the MALS
channel on the Apogee A60 Micro-PLUS but also setting the triggering threshold in this
channel, it was possible to reduce the amount of background acquired in general while
acquiring dim signals from small particles.
Unlike conventional flow cytometers that utilise PMTs, the ImageStream X Mk II
utilises highly sensitive CCDs for signal detection. Although PMTs have a much higher
dynamic range, CCDs exhibit much higher quantum efficiencies (typically 40–95% depend-
ing on their design and the wavelength of light detected versus 20% for most PMTs) and
also a markedly lower rate of dark counts (<0.001 versus 4 electrons/pixel/second) [50].
By using TDI technology, in which pixel intensities for each particle in each channel are
integrated for all time points the particle is present in the field of view of the CCD, the
limited dynamic range of CCDs can be improved. With this technology, true signals can be
amplified far above that of background, as true particles would have a much more stable
emission or scatter pattern than the background. In addition to this, triggering on the
ImageStream X Mk II occurs in all channels on all signals above CCD background, thereby
limiting rejection of potential true signals. Together, these features have previously been
demonstrated to enable detection of 20–40 nm fluorescent polystyrene nanospheres on the
ImageStream X Mk II [25]. Although it has been suggested based on Mie light scattering
theory that the usage of a 405 nm laser would improve the sensitivity of the ImageStream
X Mk II in detecting small particles, this was not the case in this study. Light scatter signals
collected from the 405 nm laser did not allow for better separation of populations from
each other nor from the background, and the number of background events was generally
higher when collecting light scatter signals from the 405 nm laser. While this result could
seem somewhat contrary to theory, identification of true signals is often a complex interplay
between the relative levels of signal to noise. Therefore, removing an optical filter would
hardly be enough to distinguish between signals and noise, and additional optimisation,
including focussing of the laser and confocal light collection, would be necessary. Besides,
laser alignment is very important in this case, as a slightly misaligned laser might cause
diminished signals from true particles, while additional noise could be introduced. How-
ever, although somewhat problematic, SSC from the 405 nm laser did allow for successful
discrimination of the non-fluorescent silica nanospheres from the background when used
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in combination with SSC from the 785 nm laser, thereby attributing to the low LoD of the
ImageStream X Mk II.
4.2. Quantification of Synthetic Nanospheres
Apart from LoD, we additionally compared the reliability of platforms in detecting
nanospheres of different sizes and termed the smallest nanosphere population quantified
with a CV of less than 20% as the functional LoQ. In addition to this, the variability in
concentration determination for each bead population was measured, which could give
an indication as to the reproducibility of measurements of particles of different sizes. This
metric additionally highlights inconsistencies in detecting particles with different physical
characteristics on each individual platform, which could also provide valuable information
as to the sensitivity, potentials and limitations of platforms in detecting and characterising
EVs, as being able to detect a certain nanosphere population and doing so reproducibly are
two different things entirely.
In this study, the Apogee A60 Micro-PLUS had the lowest LoQ of all platforms tested,
yielding concentration variabilities between 3.9% and 9.9% for all detected nanospheres.
Much of this high reproducibility could be attributed to the same factors that contribute to
the sensitivity of this platform, as described above. Additionally, the usage of a syringe
pump equipped with a highly standardised volumetric syringe (1700 series Hamilton®
GASTIGHT® syringe, Hamilton Company, Reno, NV, USA) for driving the sample com-
bined with slow sample flow rates (0.75 µL/min) also contributed to the accuracy and
reproducibility of concentration determinations. In addition to having the lowest LoQ of
all the platforms tested in this study, the Apogee A60 Micro-PLUS was also able to de-
tect significantly larger concentrations of the smallest silica and polystyrene nanospheres,
which could be attributed to all of the above-mentioned features that contribute to the
sensitivity and reproducibility of this platform. Of note, both the use of the MALS channel
for detection and triggering and approaches to reduce noise are main factors, enabling the
Apogee A60 Micro-PLUS to detect small nanospheres efficiently and reproducibly.
Even though the ImageStream X Mk II had a comparable LoD to the Apogee A60
Micro-PLUS, its LoQ was considerably higher, and significant variability was observed for
very small and very large non-fluorescent silica nanospheres. As mentioned previously,
much of this variability could be attributed to the amount of non-specific background
events in the same region as the nanospheres, which, in turn, could be attributed to the
use of the 405 nm laser for light scatter determinations by removing the notch filter. Thus,
although little background was observed in pure buffer samples, the combination of using
the 405 nm laser for scattering in this manner and the beads in buffer with added detergent
could result in the acquisition of variable amounts of background events. When looking
at the fluorescent polystyrene nanospheres, however, variabilities were much lower as
these beads were completely discriminable from the background, further strengthening
this hypothesis. When comparing the efficiency at which nanospheres with different
sizes could be quantified, the ImageStream X Mk II had a tendency to detect fewer of
the smaller nanospheres than the Apogee A60 Micro-PLUS, regardless of composition
or fluorescence properties. Although this result was somewhat surprising, there could
be a logical explanation for this in the physical properties and limitations of the optical
system. In the present study, the sample core diameter was set to the minimum of 6 µm
to keep it stable and the largest amount of particles in focus. This, however, was much
larger than what the optics allow to be in focus, which would mean that large proportions
of particles would be out of focus. This would particularly affect smaller particles with
dim light scatter and fluorescence signals, as their signals would become more dispersed
the further they are away from the focal point. This could explain why the ImageStream X
Mk II detected fewer of the smaller nanospheres than the Apogee A60 Micro-PLUS, while
the two platforms tended to detect equivalent concentrations of the larger particles. While
this would not have much of an impact on particles with large scatter profiles or with high
fluorescence values, small particles with either no or low fluorescence signals would have
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significantly lower measurable signals due to becoming more diffuse and, in some cases,
reaching levels equivalent to background light. This was somewhat verified in the results
of this study, where concentrations of particles increased with either increasing size for
non-fluorescent nanospheres or by adding fluorescence in the case of 110 nm polystyrene
nanospheres that scatter slightly less light than 180 nm silica nanospheres (Figure 2G).
In order to circumvent this issue, the ImageStream X Mk II has a combined hardware
and software feature that provides an extended depth of field (EDF). While EDF could
theoretically extend the DOF significantly and is often used when analysing cells, others
have shown that this feature does not provide an advantage in detecting small particles,
as fewer particles tend to be detected with EDF-enabled [29]. Another explanation for the
ImageStream X Mk II detecting lower concentrations of the smaller nanospheres could be
because the object detection thresholds and masking algorithms on the ImageStream X Mk
II were designed for cells and cell-sized objects. Based on this, very small dim objects might
not reach the requirements to be an object according to the INSPIRE software, thereby
excluding them from the data.
4.3. Characterisation of EVs in Blood Plasma
While measuring synthetic nanospheres provide valuable information on the raw
performance of FCM platforms in characterising particles within the EV size range albeit,
with some reservations regarding differing physical properties, EV preparations are usually
much more complex owing to their biological origin. In order to reduce the complexity of
samples containing biological EVs, researchers have employed a whole range of different
purification techniques, including differential centrifugation, density gradient centrifuga-
tion, ultra-filtration, size exclusion chromatography, polymer-based purification, affinity
purification methods. However, in order to limit the amount of pre-analytical variability
introduced in sample handling and storage, we chose to characterise EVs directly in blood
plasma in this study, which is a preferred practice for some research groups in characteris-
ing single EVs using flow cytometers aimed at keeping the method as clinically applicable
as possible [47,51–53]. We compared the ability of the different platforms to detect four
different EV phenotypes with focus on concentrations of each respective phenotype and its
intra-day, inter-day and global variability.
Even though the Apogee A60 Micro-PLUS had the lowest LoQ of all platforms in-
cluded in this study and a comparable LoD to the ImageStream X Mk II, it detected
significantly fewer single and double-labelled EV phenotypes than the ImageStream X Mk
II. The most likely explanation for this result is that excessive background stemming from
the samples causes some of the truly positive EVs to be excluded from the analysis. While
the optical configuration of the Apogee A60 Micro-PLUS has been highly optimised to
increase signals from samples while reducing much of the methodological background, it is
almost impossible to account for other entities in the sample using conventional PMT signal
detection. This would be especially evident in complex samples like blood plasma, where
several different entities share similar physicochemical properties with EVs, including
lipoproteins and protein aggregates. These observations have also been made by other
researchers previously [7], and it has been demonstrated that a large proportion of events
detected on an Apogee flow cytometer are, in fact, lipoproteins [47]. Remarkably, despite
the high background, little variability was observed in concentrations of the different EV
phenotypes investigated in this study. This is likely because the control samples and the
actual samples were affected in similar ways, which meant that background could be
successfully removed from the analysis, thereby yielding stable concentrations of EVs.
In the present study, the ImageStream X Mk II detected far greater concentrations of
single-labelled PS+, double-labelled PS+|CD41+ and PS+|CD36+ EVs than all other plat-
forms, while it also detected significantly more of the triple-labelled PS+|CD41+|CD36+
EVs than the FACS Aria III. One of the main advantages of the ImageStream X Mk II
in detecting and characterising small particles was its ability to trigger on all channels
simultaneously. By doing so, the ImageStream X Mk II was able to acquire data on all
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particles that had a signal above the camera level in at least one channel, which reduced
the risk of true particles being excluded from data analysis. An additional advantage in
the detection of EVs was using light scatter from the 405 nm laser, as this increased the
probability of particles having a signal in this channel above camera background. Thus,
in cases where FITC from phosphatidylserine expression alone was not enough to trigger
as an object, one of the other fluorescent markers or the 405 nm scatter likely had enough
signal for the particle to be triggered and collected. Therefore, even dim particles could be
included in the analysis, which likely gave the ImageStream X Mk II its superior sensitivity.
Even though the ImageStream X Mk II had the lowest inter-day variability of all platforms,
its intra-day and global variabilities in concentration determinations of EVs were some of
the highest. Although the precise nature of this is unknown, several possible explanations
could be considered. First, although collecting light scatter from the 405 nm laser improved
sensitivity, it also introduced a considerable background, which could affect samples in a
variable manner. Second, the speed beads being utilised for synchronising the two CCDs
consisted of polystyrene, which had a much higher refractive index than most EVs, which
also affected its ability to scatter light. By combining high laser powers with highly sensitive
CCDs, light scattered from these particles could have overshadowed some EVs, which were
later excluded from the analysis by being gated out as artefacts. Third, during each data
acquisition, the ImageStream X Mk II synchronised and focussed the sample core between
the two CCDs. While this would not be too problematic under normal circumstances when
measuring cells, the sample core width and flow speed were decreased significantly in
this study, which meant that some stability was sacrificed on behalf of sensitivity. Thus,
by having a slightly unstable sample core and signal integration times between samples,
additional variability could be conferred to concentration determinations. Finally, although
all of the sample preparations were performed by the same investigator, it could not be
excluded that some portion of this variability could stem from pre-analytical procedures,
which were only noticeable by virtue of the sensitivity of the ImageStream X Mk II.
Comparing the EV concentrations measured on the three different platforms to the
true physiological concentration of EVs is no simple task. Although EVs (exosomes and
microvesicles) in various biofluids have been measured quite extensively throughout the
past decade, there is little agreement in the literature concerning the concentration of
EVs in blood plasma from healthy individuals with concentrations ranging from as little
as 200 to as much as 109 EVs/µL [1,54]. Much of this disagreement stems from lack of
sensitivity on certain platforms (cFCM) to detect small particles, yielding relatively low
concentrations, while others are more sensitive to contaminating factors, such as various
species of lipoproteins and protein aggregates (nanoparticle tracking analysis, atomic force
microscopy), thereby yielding very high concentrations and skewed particle size distribu-
tions. In this study, the FACSAria III was able to detect a median 3.7 × 104 PS+ EVs/µL,
whereas the Apogee A60 Micro-PLUS was able to detect 1.01 × 105 EVs/µL and the Im-
ageStream X Mk II 8.59 × 105 EVs/µL. Two independent studies by van der Pol et al. [14]
and Arraud et al. [11] previously demonstrated that conventional flow cytometers were
able to detect less than 1% of the bulk of EVs with a lower size cut-off of 270–300 nm as
compared to quantitative immuno-TEM, which is considered by many to be the gold-
standard in characterising EVs due to its ability to detect even the smallest particles in a
sample (~1 nm) and despite the low sample throughput of this method [14] and operator
dependency of results [55]. In addition, van der Pol et al. also demonstrated that a high-
resolution flow cytometer only under-estimated the concentration of EVs in a biological
sample by 15-fold with a significantly improved lower size cut-off of 150–190 nm compared
to TEM, thus giving a 20-fold difference between conventional and high-resolution flow
cytometry [14]. This was, however, not quite the case in this study, as the FACSAria III was
able to detect approximately 37% of the PS+ EVs detected by the Apogee A60 micro-PLUS.
One of the most apparent reasons for this could be that the ability of conventional flow
cytometers to detect fluorescently labelled EVs could further be improved by up to 40-fold
by using a fluorescence trigger rather than a scatter trigger [15], a strategy which the
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authors of the present study opted for. This strategy has also been estimated to improve the
lower size cut-off of conventional flow cytometers to around 200 nm [16], which includes
a significantly larger proportion of the bulk of EVs compared to the standard triggering
strategy, as the concentration of EVs increases exponentially with decreasing size until a
peak size of between 50 and 100 nm, after which it drops off with decreasing size [11,14].
It was, however, impressive that the ImageStream X Mk II detected 8.5-fold more PS+
EVs than the Apogee A60 Micro PLUS and 23.2-fold more than the FACSAria III. Much
of this is due to the advantages of imaging flow cytometers described above, including
using low noise CCDs, TDI of each particle, and detecting even dimly fluorescent particles
due to triggering in all channels. How this translates to a lower size cut-off is uncertain,
as no groups have yet made a head-to-head comparison between concentrations and de-
tectable EV-size distributions obtained on imaging flow cytometers and other methods,
such as NTA and TEM, to the authors’ knowledge. Previously, however, Headland et al.
showed that the ImageStream X Mk II could detect fluorescent polystyrene beads as small
as 20 nm, with almost no detectable light scatter signal based solely on the fluorescence
of these nanospheres [25]. Although polystyrene beads have a much higher refractive
index than EVs, this would probably not matter in this case, as light scattering off of a
20 nm polystyrene nanosphere would likely be too dim to detect even with a high-powered
405 nm laser. As such, the ImageStream X Mk II could theoretically detect the entire size
range of EVs, provided that each EV is sufficiently fluorescent.
While describing the ability of a method to discover and detect EVs within a specific
size and fluorescence range is certainly a useful metric, other properties related to the
flow cytometric platform used are also important to consider when interpreting results.
In this study, we demonstrated that it is necessary to describe the ability of a method
to detect particles throughout the size and fluorescence range where EVs are expected
to fall, as asymmetric recovery throughout this range or excessive variability within a
certain region in this range might complicate data interpretation. In addition, it is also
important to consider which methodological platform should be used for a specific study
design, as the inherent properties of a certain platform might make it suitable for one
application and unsuitable for another. Specifically, the Apogee A60 Micro-PLUS could
determine EV concentrations very reproducibly and had the lowest intra-day and global
variabilities of all tested platforms and acceptable intra-day variabilities as well. However,
it detected far fewer EVs than the ImageStream X Mk II, which could partly stem from a
significantly lower signal-to-noise ratio and being more sensitive to other factors in the
sample, such as lipoproteins and protein aggregates. As such, the Apogee A60 Micro-PLUS
would be more suitable for use in studies, where EV concentrations are compared between
different study groups (i.e., clinical studies), while it would be less suitable in studies
used for discovery of EV phenotypes or validation of whether a specific EV phenotype is
present in a sample. On the other hand, the ImageStream X Mk II could detect far larger
concentrations of EVs of all of the investigated phenotypes than all other platforms and
could do so reproducibly with low inter-day variability in mean concentrations of EVs.
However, it had large intra-day and global variabilities and, therefore, large dispersion
in the concentrations of individual samples. Thus, the ImageStream X Mk II would be
very suitable for discovering or validating whether a specific EV phenotype is present in a
sample, while it might be less suitable for comparing EV phenotypes between different
study groups due to the large variability in determining EV concentrations.
5. Conclusions
By applying this methodology presented in this study, different strengths and weak-
nesses of platforms can be elucidated. By not only defining the smallest particle a platform
can detect but also the reproducibility of concentration determinations of several different
particles with different physical properties (e.g., size, RI, fluorescence), the performance of
a platform can be characterised across the entire range of parameters, where it is expected
for EVs to be detected. By comparatively analysing the concentrations of these beads across
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several platforms, platforms’ specific issues can be discovered and perhaps be improved
upon. Determining both relative EV concentrations and the variability in EV concentration
measurements could also help in choosing the correct platform for a study. On the one
hand, discovery-based or rudimentary characterisation studies might prefer the use of
highly sensitive methods to detect large amounts of EVs for discovering or validating the
presence of specific EV phenotypes in a sample. On the other hand, in clinical studies,
where differences in EV concentrations between groups are either not known or expected
to be small, platforms with higher reproducibility would be preferable, as these would
have a larger potential at finding true differences between patient groups by not inferring
overt methodological variability to sample concentration determinations.
In conclusion, this study contributes to a growing wealth of research that demon-
strates the necessity for researchers to know their methods and the peculiarities of the
platforms they use for EV characterisation. Although great advances have been made in
standardising EV characterisation on flow cytometers during the past few years, knowing
the limitations and possible solutions to these for each individual platform would aid
tremendously in providing reproducible and reliable results. This study attempted to lay
the ground for more robust and comprehensive comparisons of flow cytometry platforms
for the characterisation of EVs. Although extensive, this methodology for comparing
flow cytometers is far from perfect and can be improved upon in several areas, as great
advances have been made by other researchers and designated standardisation committees
in generating and reporting highly standardised results since the practical work in this
study was concluded, and incorporating these into comparisons would only strengthen
conclusions drawn from these results. Nonetheless, using this or similar methodology
for characterising and comparing platforms would allow researchers to discover different
limitations on their chosen platforms and aid them in matching suitable flow cytometry
platforms with projects based on the needs of each individual project. This would con-
tribute to improving on the reproducibility of studies and thereby increase the quality and
robustness of results in EV studies, all of which would advance the field of EV research.
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